October 16, 2007 - MIV Therapeutics Inc., a developer of coatings and drug delivery systems for cardiovascular stents, will present results from the first-in-man safety study with the its drug-eluting stent at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C.
The 15-patient study with the first human implantation of the low dose polymer-free hydroxyapatite-coated drug-eluting stent was initiated in May of 2007. Each patient was followed for four months. Principal investigator Alexandre Abizaid, M.D., Ph.D., chief of Coronary Intervention of Institute Dante Pazzanese of cardiology in Sao Paulo, Brazil, will make the presentation titled, "The MIV Polymer-Free Hydroxyapatite-Coated Sirolimus-Eluting Stent: First-in-Man Angiographic and IVUS Follow-Up Results," on Sunday, October 21 in Room 152A at 3:03 p.m. Eastern time. It is part of a practical workshop titled "First-In-Man Experiences With Drug-Eluting Stents I and Passive and Active Stent Coatings" within the scientific symposia "Innovative Devices and Futuristic Concepts I: Novel Bare Metal and Drug-Eluting Stents."
"We are looking forward to the largest-ever presence for MIV Therapeutics at the TCT conference, we believe that acceptance to present at this conference is an important recognition of the significance of our proprietary technology," said Dr. Mark Landy, president of MIV Therapeutics.
For more information: www.mivtherapeutics.com
July 02, 2024 
